# Gestational Treatment With Ursodeoxycholic Acid Compared to Placebo to Reduce Severity of Gestational Diabetes Mellitus Diagnosed at 24-28 Weeks' Gestation

> **NCT06127355** · PHASE3 · COMPLETED · sponsor: **Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia** · enrollment: 113 (actual)

## Conditions studied

- Gestational Diabetes

## Interventions

- **DRUG:** 500 mg of ursodeoxycholic acid (UDCA)
- **OTHER:** 500 mg of Placebo

## Key facts

- **NCT ID:** NCT06127355
- **Lead sponsor:** Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-03
- **Primary completion:** 2022-02-09
- **Final completion:** 2022-05-10
- **Target enrollment:** 113 (ACTUAL)
- **Last updated:** 2023-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06127355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06127355, "Gestational Treatment With Ursodeoxycholic Acid Compared to Placebo to Reduce Severity of Gestational Diabetes Mellitus Diagnosed at 24-28 Weeks' Gestation". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06127355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*